Amathus Therapeutics is developing first-in-class small molecule therapeutics targeting organelle-specific molecular chaperones to harness the benefit of positively modulating cellular stress responses. Our lead programs enhance mitochondrial function and are in development for Parkinson’s disease and renal disorders.
- Yiannis Ioannou, PhD Founder & Chair, Scientific Advisory Board
- David Weiner, MD Chief Executive Officer
- Ed Holson, PhD Chief Scientific Officer